drugset
drugset / Trial / NCT05619692

A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

NCT05619692 ↗

Phase 2 Completed 174 enrolled Supernus Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Alzheimer's Disease.

Timeline

Start
2022-11-29
Primary completion
2024-06-05
Completion
2024-07-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalzanemdor Small molecule 0.9 mg Oral

Indications

Alzheimer disease cognitive impairment with or without cerebellar ataxia